Shares of Amgen Inc. (NASDAQ:AMGN) recorded 0.22% gain during trading session on March 14th, 2019. The script traded as low as $185.89 and last traded at $187.76. 2.69 million shares changed exchanged hands during trading, an increase of 16.53% from the 30-day average session volume of 3.22M shares. The firm had previously closed at $187.35. The company has $624.31M outstanding shares, a price-to-earnings ratio of 14.90, price-to-earnings-growth ratio of 4.94and a beta of 1.21. The company has a RSI of 49.53, ATR of 3.14 and a volatility of 1.54% this week. AMGN has a 52 week low price of $163.31 and a 52 week high price of $210.19.
Investors have identified the tech company Amgen Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 117.22B, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Amgen Inc. (AMGN) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For AMGN, the company has in raw cash 6.95 billion on their books with 1.21 billion currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 37.62 billion total, with 31.25 billion as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
AMGN were able to record 10.56 billion as free cash flow during the recently reported quarter of the year, this saw their quarterly net cash flow reduce by 3.15 billion. In cash movements, the company had a total of 11.3 billion as operating cash flow.
Potential earnings growth for Amgen Inc. (AMGN)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Amgen Inc. recorded a total of 6.23 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.07% coming in sequential stages and their sales for the third quarter increasing by 0.05%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 1.1 billion trying to sell their products during the last quarter, with the result yielding a gross income of 5.13 billion. This allows shareholders to hold on to 624.31M with the revenue now reading 3050 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (3.63 cents a share).
Is the stock of AMGN attractive?
Having a look at the company’s valuation, the company is expected to record 14.76 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on AMGN sounds very interesting.
In related news, Director SUGAR RONALD D sold 2,000 shares of the company’s stock in a transaction that recorded on March 6th, 2019. The sale was performed at an average price of 188.88, for a total value of 377,760. As the sale deal closes, the Director SUGAR RONALD D now sold 2,000 shares of the company’s stock, valued at 380,000. Also, Director Jacks Tyler sold 20,000 shares of the company’s stock in a deal that was recorded on December 6th, 2019. The shares were sold at an average price of 195.41 per share, with a total market value of 8,979. Following this completion of acquisition, the SVP & CCO now holds 1,777 shares of the company’s stock, valued at 360,520. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
5 out of 23 analysts covering the stock have rated it a Buy, while 13 have maintained a Hold recommendation on Amgen Inc. stock. 0 analysts has assigned a Sell rating on the AMGN stock. The 12-month mean consensus price target for the company’s shares has been set at $206.30.